Hoechst Aktiengesellschaft

Celltech Limited

Michael Limbert

Hans-Wolfram Fehlhaber

Joachim Betz

Laszlo Vertesy

Walter Durckheimer

Gerhard Dickneite

Elmar Schrinner

Hans-Ulrich Schorlemmer

Hans-Harald Sedlacek

Uwe Gerlach

Ulrich Gebert

Gerhard Seibert

Rudolf Lattrell

Jurgen Blumbach

Herbert Kogler

Bimal N Ganguli

Astrid Markus

Hiristo Anagnostopulos

Mark William Bodmer

Heinz Hanel

Matthias Helsberg

Norbert Krass

Rolf Horlein

Karl-Heinz Scheunemann

Norbert Klesel

Laslo Vertesy

Ramaiyer R Chandran

Dieter-Andreas Sukatsch

Theo Wollmann

Gerald Anthony Higgs

A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy of prophylaxis of disorders associated with undesirable high levels of TNF, e.g. septic or endotoxic shock and immunoregulatory and inflammatory disorders, which comprises an antibody to TNF or a TNF binding fragment thereof and a xanthine derivative. Particular preferred xanthine derivatives are 3,7-dimethyl-1(5-oxo-hexyl)xanthine (known as Pentoxifylline or TRENTAL) and 1-(5-hydroxy-5-methylhexyl)-3-methylxanthine and similar compounds. The anti-TNF antibody or fragment is preferably monospecific especially a humanized recombinant antibody or fragment.

Use of antibodies to TNF or fragments derived thereof and xanthine

Desmethylbalhimycin, a compound of the formula C.sub.65 H.sub.71 Cl.sub.2 N.sub.9 O.sub.24, desmethylleucylbalhimycin, a compound of the formula C.sub.59 H.sub.60 Cl.sub.2 N.sub.8 O.sub.23, desglucobalhimycin, a compound of the formula C.sub.60 H.sub.63 Cl.sub.2 N.sub.9 O.sub.19, ureidobalhimycin, a compound of the formula C.sub.67 H.sub.74 Cl.sub.2 N.sub.10 O.sub.25, desmethyl-desglucobalhimycin, a compound of the formula C.sub.59 H.sub.61 Cl.sub.2 N.sub.9 O.sub.19 and balhimycin V, a compound of the formula C.sub.73 H.sub.84 Cl.sub.2 N.sub.10 I.sub.26, methylbalhimycin, a compound of the formula C.sub.67 H.sub.75 Cl.sub.2 N.sub.9 O.sub.24 and balhimycin R, a compound of the formula C.sub.72 H.sub.83 Cl.sub.2 N.sub.9 O.sub.28, have an antibiotic action.

Glycopeptides, a process for their preparation and their use

Novel glycopeptides, a process for their preparation and their use Desmethylbalhimycin, a compound of the formula C.sub.65 H.sub.71 Cl.sub.2 N.sub.9 O.sub.24, desmethylleucylbalhimycin, a compound of the formula C.sub.59 H.sub.60 Cl.sub.2 N.sub.8 O.sub.23, desglucobalhimycin, a compound of the formula C.sub.60 H.sub.63 Cl.sub.2 N.sub.9 O.sub.19, ureidobalhimycin, a compound of the formula C.sub.67 H.sub.74 Cl.sub.2 N.sub.10 O.sub.25, desmethyl-desglucobalhimycin, a compound of the formula C.sub.59 H.sub.61 Cl.sub.2 N.sub.9 O.sub.19 and balhimycin V, a compound of the formula C.sub.73 H.sub.84 Cl.sub.2 N.sub.10 I.sub.26, methylbalhimycin, a compound of the formula C.sub.67 H.sub.75 Cl.sub.2 N.sub.9 O.sub.24 and balhimycin R, a compound of the formula C.sub.72 H.sub.83 Cl.sub.2 N.sub.9 O.sub.28, have an antibiotic action.

Glycopeptides a process for their preparation and their use

Compounds 31668P and 31668U, a process for their production and their use. Compound 31668P and compound 31668U with the formulae ##STR1## have an antibiotic and an antitumor action.

Compounds 31668P and 31668U, a process for their production and their use

Tetracyclic antibiotics and processes for their preparation .beta.-Lactam antibiotics of the formula I, and their pharmaceutically tolerable salts ##STR1## where X is (CH.sub.2).sub.0-2, CR(a)R(b), O, SO.sub.0-2 or NR(c),

Tetracyclic antibiotics and processes for their preparation

Pharmaceutical combination preparations containing cefotaxime and at least one xanthine derivative are suitable for the treatment of bacterial infectious diseases and for the treatment of septic shock.

Pharmaceutical combination preparations containing cephalosporin and

A pharmaceutical formulation having a synergistic anti-bacterial activity and comprising

Pharmaceutical formulation for the treatment of bacterial infections

Heterocyclic sulfides of the general formula heterocycle-S-R, a process for their preparation and, in particular, their use for immunostimulation, immunorestoration and cytostatic treatment, and pharmaceutical agents, which contain a sulfide of this type, for these indications.

1,3-thiazoles and their use as immunomodulators

The use of cephem compounds of the general formula I ##STR1## to increase the immunological responsiveness of mammals and formulations which contain an effective content of cephem compounds of the general formula I.

Use of cephem compounds as immunomodulators

Growing community of inventors

Hofheim am Taunus, Germany

Michael Limbert